Joshua Foukas Sells 306 Shares of USANA Health Sciences, Inc. (USNA) Stock

USANA Health Sciences, Inc. (NYSE:USNA) insider Joshua Foukas sold 306 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The shares were sold at an average price of $129.27, for a total value of $39,556.62. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Joshua Foukas also recently made the following trade(s):

  • On Thursday, September 6th, Joshua Foukas sold 6,531 shares of USANA Health Sciences stock. The shares were sold at an average price of $125.79, for a total value of $821,534.49.

USNA stock traded down $2.55 during midday trading on Friday, hitting $127.20. The company had a trading volume of 118,602 shares, compared to its average volume of 113,269. USANA Health Sciences, Inc. has a 52 week low of $55.50 and a 52 week high of $137.95. The company has a market capitalization of $3.15 billion, a P/E ratio of 27.75 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 24th. The company reported $1.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.11 by $0.25. USANA Health Sciences had a return on equity of 29.50% and a net margin of 7.16%. The firm had revenue of $301.50 million for the quarter, compared to analysts’ expectations of $278.41 million. During the same period in the previous year, the firm earned $0.98 earnings per share. The business’s revenue was up 17.3% compared to the same quarter last year. equities analysts forecast that USANA Health Sciences, Inc. will post 4.9 EPS for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Robecosam AG purchased a new position in shares of USANA Health Sciences during the first quarter valued at approximately $126,000. SG Americas Securities LLC purchased a new position in shares of USANA Health Sciences during the first quarter valued at approximately $137,000. O Shaughnessy Asset Management LLC purchased a new position in shares of USANA Health Sciences during the first quarter valued at approximately $179,000. Burney Co. purchased a new position in shares of USANA Health Sciences during the first quarter valued at approximately $206,000. Finally, Susquehanna Fundamental Investments LLC purchased a new position in shares of USANA Health Sciences during the first quarter valued at approximately $206,000. 56.40% of the stock is currently owned by hedge funds and other institutional investors.

Separately, Pivotal Research reiterated a “hold” rating and issued a $135.00 price objective on shares of USANA Health Sciences in a research report on Wednesday, July 25th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $135.00.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.

Further Reading: Growth Stocks

Insider Buying and Selling by Quarter for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit